All rights reserved. It is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains. Pneumonia caused by Chlamydia pneumoniae, Haemophilus Influenzae, Moraxella catarrhalis, Legionella pneumophila, Mycoplasma pneumoniae and Streptococcus pneumoniae. Skin and Skin structures infections. Sexually transmitted diseases, especially non-gonococcal urethritis and cervicitis.
Most side effects are mild in severity.
Reported side effects inlcude nausea, vomiting, diarrhea or abdominal pain. Use in pregnant women has not been studied sufficiently but animal studies have shown no harm done to the fetus. Meningitis Ceftriaxone is considered the Drug of Choice for Presumptive therapy of Meningitis. In severe cases the dosage may be raised to 4gm, administered once daily. It was originally developed by Fujisawa Pharmaceuticals of Osaka, Japan and licensed to Hikma Pharmaceuticals.